Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Apr 7, 2009

Premium

Helaman Escobar is leaving his post as the director of the DNA sequencing and genomics core facility at the University of Utah in order to head the DNA sequencing operation at Eurofins' Operon/MWG in Huntsville, Ala. The University of Utah is currently seeking a replacement for his position.


John Keilty has been promoted to vice president of information technology and informatics at Infinity Pharmaceuticals, a cancer drug discovery and development company. Prior to joining Infinity in 2002, he worked for Millennium Pharmaceuticals, where he was responsible for sequence analysis, genotyping, application development, and DNA sequencing. Keilty holds a BA in biology from Clark University.


Lutz Kirchrath has become managing director of European field operations at NuGen Technologies, where he will lead both sales and technical support functions. Most recently, Kirchrath was European pharmaceutical district manager for Affymetrix. Prior to that, he spent nearly five years in sales development and applications support with Amersham Pharmacia Biotech in Freiburg, Germany. Kirchrath holds a doctorate in microbiology and molecular genetics, and a diploma in biology, from the Heinrich-Heine Universität in Düsseldorf, Germany.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.